374 related articles for article (PubMed ID: 26391972)
1. In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release.
Andreas CJ; Chen YC; Markopoulos C; Reppas C; Dressman J
Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):39-50. PubMed ID: 26391972
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal release behaviour of modified-release drug products: dynamic dissolution testing of mesalazine formulations.
Goyanes A; Hatton GB; Merchant HA; Basit AW
Int J Pharm; 2015 Apr; 484(1-2):103-8. PubMed ID: 25721685
[TBL] [Abstract][Full Text] [Related]
3. Can dosage form-dependent food effects be predicted using biorelevant dissolution tests? Case example extended release nifedipine.
Andreas CJ; Tomaszewska I; Muenster U; van der Mey D; Mueck W; Dressman JB
Eur J Pharm Biopharm; 2016 Aug; 105():193-202. PubMed ID: 27322002
[TBL] [Abstract][Full Text] [Related]
4. Release of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various pH Levels.
Abinusawa A; Tenjarla S
Adv Ther; 2015 May; 32(5):477-84. PubMed ID: 25951927
[TBL] [Abstract][Full Text] [Related]
5. Prediction of the Oral Pharmacokinetics and Food Effects of Gabapentin Enacarbil Extended-Release Tablets Using Biorelevant Dissolution Tests.
Yamaguchi Ikeuchi S; Kambayashi A; Kojima H; Oku N; Asai T
Biol Pharm Bull; 2018; 41(11):1708-1715. PubMed ID: 30381671
[TBL] [Abstract][Full Text] [Related]
6. A novel dissolution method relevant to intestinal release behaviour and its application in the evaluation of modified release mesalazine products.
Schellekens RC; Stuurman FE; van der Weert FH; Kosterink JG; Frijlink HW
Eur J Pharm Sci; 2007 Jan; 30(1):15-20. PubMed ID: 17085024
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic investigation of the negative food effect of modified release zolpidem.
Andreas CJ; Pepin X; Markopoulos C; Vertzoni M; Reppas C; Dressman JB
Eur J Pharm Sci; 2017 May; 102():284-298. PubMed ID: 28286289
[TBL] [Abstract][Full Text] [Related]
8. Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form.
Jantratid E; De Maio V; Ronda E; Mattavelli V; Vertzoni M; Dressman JB
Eur J Pharm Sci; 2009 Jun; 37(3-4):434-41. PubMed ID: 19491035
[TBL] [Abstract][Full Text] [Related]
9. Dissolution testing of modified release products with biorelevant media: An OrBiTo ring study using the USP apparatus III and IV.
Reppas C; Vrettos NN; Dressman J; Andreas CJ; Miyaji Y; Brown J; Etherson K; Hanley S; Karkossa F; Karlsson E; Klein S; Maier GM; McAllister M; Mistry N; Rosenblatt K; Schäfer KJ; Smith KL; Tomaszewska I; Williams J; Winge F; Vertzoni M
Eur J Pharm Biopharm; 2020 Nov; 156():40-49. PubMed ID: 32882421
[TBL] [Abstract][Full Text] [Related]
10. Impairment of the in vitro drug release behaviour of oral modified release preparations in the presence of alcohol.
Fadda HM; Mohamed MA; Basit AW
Int J Pharm; 2008 Aug; 360(1-2):171-6. PubMed ID: 18547758
[TBL] [Abstract][Full Text] [Related]
11. A Biopredictive In Vitro Comparison of Oral Locally Acting Mesalazine Formulations by a Novel Dissolution Model for Assessing Intraluminal Drug Release in Individual Subjects.
Karkossa F; Klein S
J Pharm Sci; 2018 Jun; 107(6):1680-1689. PubMed ID: 29499277
[TBL] [Abstract][Full Text] [Related]
12. Physiological bicarbonate buffers: stabilisation and use as dissolution media for modified release systems.
Fadda HM; Merchant HA; Arafat BT; Basit AW
Int J Pharm; 2009 Dec; 382(1-2):56-60. PubMed ID: 19666093
[TBL] [Abstract][Full Text] [Related]
13. Interaction between fed gastric media (Ensure Plus®) and different hypromellose based caffeine controlled release tablets: comparison and mechanistic study of caffeine release in fed and fasted media versus water using the USP dissolution apparatus 3.
Franek F; Holm P; Larsen F; Steffansen B
Int J Pharm; 2014 Jan; 461(1-2):419-26. PubMed ID: 24342711
[TBL] [Abstract][Full Text] [Related]
14. Effect of Coadministered Water on the In Vivo Performance of Oral Formulations Containing N-Acetylcysteine: An In Vitro Approach Using the Dynamic Open Flow-Through Test Apparatus.
Sager M; Schneider F; Jedamzik P; Wiedmann M; Schremmer E; Koziolek M; Weitschies W
Mol Pharm; 2017 Dec; 14(12):4272-4280. PubMed ID: 29064257
[TBL] [Abstract][Full Text] [Related]
15. Novel mesalamine-loaded beads in tablets for delayed release of drug to the colon.
Nguyen C; Christensen JM; Ayres JW
Pharm Dev Technol; 2012; 17(1):73-83. PubMed ID: 20923254
[TBL] [Abstract][Full Text] [Related]
16. Physiological Considerations and In Vitro Strategies for Evaluating the Influence of Food on Drug Release from Extended-Release Formulations.
Koziolek M; Kostewicz E; Vertzoni M
AAPS PharmSciTech; 2018 Oct; 19(7):2885-2897. PubMed ID: 30155808
[TBL] [Abstract][Full Text] [Related]
17. On the usefulness of compendial setups and tiny-TIM system in evaluating the in vivo performance of oral drug products with various release profiles in the fasted state: Case example sodium salt of A6197.
Schilderink R; Protopappa M; Fleth-James J; Vertzoni M; Schaefer K; Havenaar R; Kulla I; Metzger M; Reppas C
Eur J Pharm Biopharm; 2020 Apr; 149():154-162. PubMed ID: 32057905
[TBL] [Abstract][Full Text] [Related]
18. Dissolution of Commercially Available Mesalamine Formulations at Various pH Levels.
Tenjarla S
Drugs R D; 2015 Jun; 15(2):211-5. PubMed ID: 26115756
[TBL] [Abstract][Full Text] [Related]
19. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB
Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487
[TBL] [Abstract][Full Text] [Related]
20. Performance Evaluation of Montelukast Pediatric Formulations: Part I-Age-Related In Vitro Conditions.
Guimarães M; Somville P; Vertzoni M; Fotaki N
AAPS J; 2022 Jan; 24(1):26. PubMed ID: 35013835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
